Published under our former name, glp1.blog. Same brief, new masthead.
50 vs 33 vs 47.
Novo sued Lilly on Tuesday and asked a judge to stop the ads by Friday. The whole fight is three numbers, and the one in 700 million living rooms is not the one Novo likes.
One television ad has been seen more than 700 million times since late April. It says patients on Zepbound lose 50 pounds on average, against 33 on Wegovy. On Friday, Novo Nordisk asked a federal judge to make it stop running.
Read that sequence again. Lawsuit Tuesday. Emergency injunction request Friday. Three days. Companies do not move at that speed for pride. They move at that speed for money.
The escalation
Tuesday’s suit, in federal court in New Jersey, said Lilly’s ads mislead consumers by comparing Lilly’s highest doses against Novo’s lower ones. Novo told Lilly to pull them. Lilly declined. So on Friday Novo went back to the judge and asked for a preliminary injunction on an expedited basis, a court order to yank the ads while the case plays out.
The whole war is three numbers.
the three numbers
| claim | avg loss | from |
|---|---|---|
| Zepbound, per the ad | 50 lb | the only head-to-head trial |
| Wegovy 2.4 mg, per the ad | 33 lb | same trial, lower dose |
| Wegovy 7.2 mg, Novo's answer | 47 lb | Novo's study; selling since March |
Novo’s argument: the 33 belongs to the 2.4 milligram dose. Its 7.2 milligram Wegovy has been on pharmacy shelves since March and posted 47 pounds. The comparison was true once. Novo says it stopped being true four months ago, and every airing since has been writing a false number into the market.
Lilly’s answer is one sentence long. Novo “has never tested its highest doses of semaglutide against Lilly’s tirzepatide medicines in any clinical trial.” The 50 vs 33 came from the only study that ever put the two drugs head to head. Until someone runs the new matchup, Lilly says, its number is the only real one.
Edition 1 said market leaders publish trial data and companies losing share sue about it. The 47 does not soften that call. It sharpens it. If you believe your new dose matches theirs, you run the head-to-head and print your own commercial. You sue when you need the correction to arrive faster than the data can.
Why an ad is worth suing over
Here is the thing about a drug ad. You are not the customer. You are the sales force.
Novo’s own complaint says it plainly: consumers form their understanding of these drugs from advertising, because they cannot read trial data the way clinicians do. A patient who has seen “50 vs 33” seven times does not ask their doctor for semaglutide. They ask for Zepbound, by name, and most of the time that is what gets prescribed.
And the funnel got shorter. When the drugmaker also runs the pharmacy, the ad is not brand awareness, it is the storefront. Zepbound vials run $299 to $449 on LillyDirect depending on dose. Wegovy pens are $349 on NovoCare, $399 for the high dose. See the ad, click, check out. Every impression is a step from a couch to a cart. That is why 700 million of them are worth suing over, and why the remedy Novo wants is not just damages but corrective advertising, a court-ordered un-ringing of the bell.
The past four months are gone. The injunction is about the next four, and about one date in particular: Novo needs that ad dark before August 5, because the only thing worse than reporting a down half-year is reporting it while your rival’s number plays in the commercial break.
The wrapper angle, briefly
The telehealth layer sells both companies’ drugs and controls neither company’s story.
Hims, Ro, and GoodRx are the shelf where Foundayo, Lilly’s $149 pill, sits. Hims is already fighting a Novo patent suit on top of it. Now the two manufacturers whose drugs the wrappers depend on are in open court over whose efficacy number is real, and the wrapper’s customer sees the crossfire before the wrapper does.
When the suppliers fight about the truth, the middleman sells confusion at retail.
Sit out and sell the map. The wrappers cannot pick a side; they stock both shelves. But when the two suppliers are in federal court over whose number is real, the middleman who explains the fight in plain language becomes the only trusted counter in the store. Help me decide is the last moat an access company has left.
Watching for
- The injunction ruling. Novo asked for expedited treatment, so the calendar is the story now.
- Whether Lilly pulls the ad, or doubles the spend while it still can.
- August 5, before the market opens: Novo reports H1. The company guided in February to a 5 to 13% decline, narrowed in May to 4 to 12. That guidance gets its first reality check.
That is the brief. Same time Tuesday.